A5010547787- Health Systems, Economic Evaluations, Quality of Life
- Telemedicine and Telehealth Implementation
- Mobile Health and mHealth Applications
- Hematopoietic Stem Cell Transplantation
- Health Literacy and Information Accessibility
- Rheumatoid Arthritis Research and Therapies
- Renal Transplantation Outcomes and Treatments
- Amyotrophic Lateral Sclerosis Research
- Neurogenetic and Muscular Disorders Research
- Digital Mental Health Interventions
- Acute Lymphoblastic Leukemia research
- Biosimilars and Bioanalytical Methods
- Organ Donation and Transplantation
- Ear Surgery and Otitis Media
- Chronic Lymphocytic Leukemia Research
- Pharmaceutical studies and practices
- Quality and Safety in Healthcare
- T-cell and B-cell Immunology
- Breast Cancer Treatment Studies
- Business Process Modeling and Analysis
- Bone health and osteoporosis research
- Multiple Sclerosis Research Studies
- Tracheal and airway disorders
- Academic Publishing and Open Access
- Neurological Complications and Syndromes
Burrell Behavioral Health
2020-2024
Anita B (Czechia)
2022
Illinois College
2022
University of Illinois Urbana-Champaign
2022
Corvinus University of Budapest
2022
Obuda University
2022
Sanofi (France)
2007
Sanofi (Spain)
2006
Health Economics and Outcomes Research (United Kingdom)
2003
Boehringer Ingelheim (Germany)
1997
Digital health has accelerated, in part, due to the recent COVID-19 pandemic terms of both implementation and acceptability.However, while digitalization healthcare brings an opportunity improve quality care, this creates a need for sustainability through funding these technologies by payers.Traditional innovations such as pharmaceuticals are rigorously evaluated technology assessment (HTA) bodies many countries advise payers on how scarce funds can be efficiently distributed.The aim study...
Abstract The real-world clinical and economic burden of graft-versus-host disease (GVHD) following allogeneic hematopoietic stem cell transplantation has not been comprehensively studied in France. Clinical outcomes, healthcare resource utilization costs associated with acute GVHD (aGVHD), chronic (cGVHD), plus (a+cGVHD) versus no were compared using French administrative claims data. After propensity score matching, 1934, 408, 1268 matched pairs retained for the aGVHD, cGVHD, a+cGVHD...
Acute graft-vs-host disease (aGVHD) is a serious complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT), yet there are limited data on the clinical and economic burden aGVHD in Germany. This real-world study aimed to evaluate outcomes among patients Germany with or without after allo-HSCT. retrospective cohort used administrative claims extracted from German statutory health insurance database. Eligible adult underwent allo-HSCT between 1 January 2009 31 December 2017...
Introduction The use of information technology within health systems has emerged over the years and current pandemic further catalyzed this development. As a result, various definitions eHealth have emerged. Our objective was to provide an overview available on internet complement traditional (“white”) literature search. Methods We adapted methodological guidelines from Cochrane Handbook management sciences mirror search in bibliographic databases. A comprehensive Google performed July 2020...
SUMMARYWe have developed an economic model around the patient level data from pivotal clinical trial for Copaxone® (glatiramer acetate), combined with published cost and natural history data, to demonstrate cost-effectiveness in relapsing-remitting multiple sclerosis (RRMS). Based upon analysis over 8 years, per relapse avoided disability unit was £11,000 £8,862 respectively. To facilitate comparison other therapies across disease areas we also calculated quality adjusted life year (QALY)....
Introduction Digital transformation has been promoted by the World Health Organization (WHO), Food and Drug Administration (FDA) European Commission (EC) to help improve health outcomes. To ensure sustainability, digital interventions (DHI) require funding payers. Evidence-informed decision policy making requires an assessment of impact on relevant outcomes vs current healthcare practice. Various national international organizations are involved in creating or guiding development standards...
Hemophilia B is characterized by a deficiency of clotting factor IX (FIX), leading to excessive bleeding. commonly treated using replacement FIX therapy, which may be administered prophylactically or on-demand following bleeding episode. Previous research has found high health care resource use (HCRU) and costs among Medicare commercially insured people with hemophilia (PwHB), therapy being primary driver costs.
Introduction The diffusion of digital health interventions (DHIs) requires agreement on a minimum information framework to define them. ISPOR Digital Health (DH) Special Interest Group (SIG) developed the PICOTS-ComTeC based upon systematic review and Delphi study. It is an enriched version traditional PICOTS widely adopted in technology assessment (HTA). ComTeC stands for communication, technology, context. Methods that included Shannon–Weaver model AHRQ Quality Measures, geography, World...
SummaryPrudent management for glue ear currently entails a month period of watchful waiting before grommet insertion if the problem has not been resolved. The costs administering Mucodyne during and potential resources released from reduction in number insertions were assessed perspective National Health Service (NHS) UK. A decision analysis model was used to estimate probability resolution with both approaches, them combined resource implications surgery its outcomes. cost difference...
Introduction Umbrella digital health term (DHT) (digital health, eHealth, mHealth, telehealth, and telemedicine) definitions contain insufficient information about patient value for economics outcomes research technology assessment (HTA) purposes. Qualitative content analysis of secondary DHT (e.g., telesurgery teleradiology) was performed by the ISPOR Digital Health Special Interest Group to determine if they were more useful Methods Secondary extracted from a previous scoping review...
SummaryThe introduction of a new class drugs, the taxoids, has dramatically improved outlook for patients with advanced, metastatic breast cancer. Second-line monotherapy most effective taxoid, docetaxel, in anthracycline-resistant cancer, shows an overall response rate up to 55% this patient population. Increased is associated quality life these patients.We carried out cost analysis determine economic benefits being state compared other health states advanced cancer: stable, progressive or...